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BACKGROUND Bioresorbable scaffolds (BRS) have the potential to
revolutionize the treatment of coronary artery disease. To date,
limited trial data have demonstrated favorable short- and longer-term
clinical outcomes up to a maximum of 5 years. However, these ob-
servations have been limited to patients presenting with ‘simple’
coronary lesions. Outcomes following BRS use in complex lesions
have been described by a few registries but remain poorly character-
ized. We report the clinical outcomes of our “real-world” experience
following BRS implantation in a patient cohort that includes a high
prevalence of complex lesions.
METHODS A retrospective analysis of consecutive patients who un-
derwent percutaneous coronary intervention (PCI) with BRS
(ABSORB; Abbott Vascular, Santa Clara, CA) in 2 centers in Milan be-
tween May 2012 and April 2015.
RESULTS The mean age was 63.810.7 years. The prevalence of dia-
betes mellitus was 25.8%, chronic kidney disease (estimated glomer-
ular ﬁltration rate < 60 ml/min/1.732) was 19.8%, and 13.7% of patients
presented with an acute coronary syndrome. With regards to lesion
characteristics, BRS were implanted in ACC/AHA Type B2/C lesions
(74.3%), CTO (6.0%), bifurcations (46.9%), in-stent restenosis (4.9%),
and left main coronary artery (2.6%). The main target vessel was the
left anterior descending artery (61.7%). The mean SYNTAX score was
17.3  10.4. Meticulous lesion preparation and aggressive post-dila-
tion was recommended for all cases with pre- and post-dilation per-
formed in 98.0% and 99.7%, respectively. A scoring balloon was
utilized in 14.6%. Intravascular ultrasound (IVUS) was utilized in
83.7% of patients to guide therapy. The median follow-up period was
441 days (interquartile range 150 to 503 days). The incidence of major
adverse cardiac events (MACE; deﬁned as a combination of all-cause
death, follow-up myocardial infarction and target vessel revasculari-
zation) occurred in 10.1% at 1-year follow-up (calculated with Kaplan–
Meier analysis). All-cause death occurred in 2 patients (non-cardiac
death). The incidence of target lesion revascularization (per lesion)
and vessel revascularization were 6.3% and 8.9%, respectively. Deﬁ-
nite scaffold thrombosis occurred in 2 patients (1.2%), the ﬁrst
following BRS implantation for the treatment of ST-elevation MI and
the second was late scaffold thrombosis in a patient that prematurely
stopped clopidogrel 2 months after BRS implantation.
CONCLUSIONS Our “real-world” BRS experience that included a high
prevalence of complex lesions demonstrated excellent clinical out-
comes at 1-year. Notably, the incidence of scaffold thrombosis was low
(1.0% at 1-year). Meticulous lesion preparation with non-compliant or
scoring balloons and IVUS-guided BRS implantation are likely to be
important factors in optimizing outcomes and reducing clinical
events.
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BACKGROUND The number and distribution of stent struts has been
previously reported to affect neointimal coverage of metallic drug-
eluting stents (DES), and stented areas with fewer struts and larger
inter-strut angles have been associated with excess neointimal hy-
perplasia compared to areas with more crowded struts. Everolimus-
eluting bioresorbable scaffolds (BRS) are novel coronary implants
that provide short-term vascular scaffolding combined with drug-
delivery capability. However, the thicker struts of current generation
BRS create areas of low endothelial shear stress, which maycontribute to neointimal formation. The aim of the present study is
to investigate the relationship between the number and distribution
of BRS struts and neointimal coverage using optical coherence to-
mography (OCT).
METHODS This study includes 35 patients (42 lesions) treated with
BRS and followed-up with coronary angiography and OCT at 12 (11.8 
2.6) months after the index procedure. All patients were prescribed
lifelong aspirin (100 mg/d) and prasugrel (10 mg/d) for at least 6
months according to local institutional guidelines. Cross sectional
areas (CSA) of OCT images were analyzed at 1-mm intervals. Scaffold
area and neointimal thickness were evaluated. Additionally, scaffold
eccentricity (SE) was deﬁned as follows: SE ¼ (maximum diameter –
minimum diameter)/ maximum diameter. To assess the impact of
strut distribution, CSAs of BRS were divided into four regions. The
average neointimal thickness (ANT) and the number of struts in each
region were measured. The number of struts in each region was
classiﬁed into 1, 2, 3 and  4. The ANT acquired in each area was
divided by the ANT of all struts in the same CSA to describe an ANT
unevenness score, and its maximum and minimum values were
deﬁned as maximum and minimum unevenness score.
RESULTS The mean age of the study population was 5810 years and
23 (65%) were males. Mean scaffold diameter and length were
3.170.37 and 19.95.2 mm, respectively. Pre-dilatation was per-
formed in almost all lesions (90%) and post-dilatation rate was 72%.
There was a signiﬁcant difference in the unevenness score between
regions with different strut numbers (unevenness score ¼ 1.040.34
in regions with 1 strut (n¼401); 0.970.25 in regions with 2 struts
(n¼512); 1.000.25 in regions with 3 struts (n¼664); and 1.040.20 in
regions with 4 struts (n¼691); p¼0.01). A positive signiﬁcant corre-
lation was observed between SE in each CSA and the dispersion
(heterogeneity) of neointimal proliferation in the same CSA, which
was expressed as maximum unevenness score – minimum uneven-
ness score (n¼631, R¼0.10, p¼0.02).
CONCLUSIONS Unlike metallic DES, not only spare distribution of
struts but also crowding of struts is associated with increased neo-
intimal proliferation after BRS implantation. In addition, SE is asso-
ciated with uneven neointimal proliferation. Adequate lesion
preparation prior to BRS implantation is therefore recommended so
that BRS can expand as evenly as possible.
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BACKGROUND The data concerning the use of bioresorbable vascular
scaffolds (BVS) for coronary chronic total occlusion lesions (CTO) are
limited. The aim of the study was to evaluate the early and long-term
clinical outcomes of CTO stenting with BVS.
METHODS The study is a prospective, nonrandomized clinical pilot
registry of patients with CTO lesion located in a major coronary ar-
tery, treated with everolimus-eluting scaffolds. Patients were eligible
if they had symptoms and/or documented reversible myocardial
ischemia, with the presence of viable myocardium in territory sup-
plied by the occluded vessel, assessed by cardiac magnetic resonance
imaging (CMRI). Patients with reference vessel diameter above
4 mm, metallic stents in the target vessel, excessive calcium and
tortuosity were excluded. Subjects were enrolled after successful
recanalization of the target vessel, conﬁrmed intraluminal distal wire
position with no major intraprocedural complications. All patients
were instructed to remain on DAPT for 12 months post procedure,
and then lifelong on aspirin alone. Clopidogrel was used until March
2014, when it was replaced with ticagrelor for at least three months
post procedure.
